NCT04083599 2026-03-16
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
Clinical Trials
52 trialsNCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07397338 2026-02-09
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT07392541 2026-02-06
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
Tongji Hospital
Phase 1/2 Recruiting
NCT06428409 2026-01-22
MK-9999-02A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06548412 2026-01-20
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT03281369 2025-12-15
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT04956640 2025-09-25
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Phase 1/2 Recruiting
NCT06531434 2025-09-22
Establishing Best Treatment Strategy for T4 Esophageal Cancer
National Cheng-Kung University Hospital
Phase 1/2 Recruiting
NCT06956716 2025-05-04
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
Zhejiang University
Phase 1/2 Recruiting
NCT02795988 2025-04-16
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Imugene Limited
Phase 1/2 Completed
NCT04278287 2024-12-13
Chemoradiotherapy in Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT04989218 2024-11-05
ICC
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT00072787 2024-09-03
Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer
Taiho Oncology, Inc.
Phase 1/2 Completed
NCT03267316 2024-08-22
CANFOUR
Cantargia AB
Phase 1/2 Completed
NCT06173986 2023-12-18
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Shanghai Chest Hospital
Phase 1/2 Recruiting
NCT03684811 2023-11-18
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Novo Nordisk A/S
Phase 1/2 Completed
NCT03649321 2023-11-09
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT02324543 2023-07-21
Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT05116891 2023-07-03
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
Phase 1/2 Completed
NCT03410030 2023-04-18
AA NABPLAGEM
HonorHealth Research Institute
Phase 1/2 Completed
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT03085914 2022-09-23
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
Phase 1/2 Completed
NCT05173142 2022-03-08
HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors
Hutchmed
Phase 1/2 Unknown
NCT02128282 2021-10-22
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Senhwa Biosciences, Inc.
Phase 1/2 Completed
NCT00064259 2021-02-17
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT04733521 2021-02-02
A Phase 1/2 Study of SC-43 in Combination With Cisplatin
RaND Biosciences
Phase 1/2 Unknown
NCT02992340 2021-01-14
Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC
ASLAN Pharmaceuticals
Phase 1/2 Terminated
NCT00565370 2020-01-18
Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
Asan Medical Center
Phase 1/2 Completed
NCT03697239 2019-06-11
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
University of California, San Diego
Phase 1/2 Withdrawn
NCT03797443 2019-05-31
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Piedmont Cancer Institute
Phase 1/2 Withdrawn
NCT03908333 2019-05-30
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Medical College of Wisconsin
Phase 1/2 Withdrawn
NCT01893801 2019-05-29
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Pancreatic Cancer Research Team
Phase 1/2 Completed
NCT01783951 2018-07-19
Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer
Capital Medical University
Phase 1/2 Completed
NCT02446574 2017-10-24
Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma
ChineseAMS
Phase 1/2 Completed
NCT03311789 2017-10-17
Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT01730222 2017-09-01
PACT-19
IRCCS San Raffaele
Phase 1/2 Completed
NCT00544362 2016-05-30
Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Phase 1/2 Completed
NCT02575859 2015-10-15
Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 1/2 Completed
NCT01525771 2015-06-29
XPID
Asan Medical Center
Phase 1/2 Completed
NCT01284413 2014-07-01
Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer
Kansai Hepatobiliary Oncology Group
Phase 1/2 Completed
NCT00719550 2013-12-05
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer
Amgen
Phase 1/2 Completed
NCT01611506 2013-01-09
Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer
Centre Hospitalier Universitaire Vaudois
Phase 1/2 Terminated
NCT00445861 2012-06-11
Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
Swiss Cancer Institute
Phase 1/2 Completed
NCT00002984 2012-05-24
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT01348009 2012-03-13
Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
Genta Incorporated
Phase 1/2 Unknown
NCT00003332 2011-03-28
Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer
NYU Langone Health
Phase 1/2 Completed
NCT00933816 2010-11-25
SILIUS
Kindai University
Phase 1/2 Completed
NCT00209690 2010-05-26
Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.
Hokkaido Gastrointestinal Cancer Study Group
Phase 1/2 Completed